TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study published in Nature Communications reports that imidazole propionate (ImP), a molecule made by some gut bacteria, was associated with Alzheimer’s-related biological markers and faster cognitive decline. Experiments in mice also linked ImP exposure to abnormal amyloid and tau accumulation. The findings do not establish that ImP causes Alzheimer’s in people or show that lowering it prevents disease.
Researchers report that imidazole propionate (ImP), a molecule produced by some gut bacteria, was linked to Alzheimer’s-related changes in mice and to biological markers and faster cognitive decline among people followed in a Wisconsin research cohort. The study, published in Nature Communications, points to ImP as a possible research target, but does not show that the molecule causes Alzheimer’s disease in people or that lowering it would prevent the disease.
The team, led by researchers at the University of Wisconsin–Madison, studied ImP because previous work had found differences in gut microorganisms between people with Alzheimer’s disease and healthy individuals. ImP is made by certain bacteria as they process histidine, an amino acid that people need. Its production varies, and the researchers say bacteria that produce it can be present without being abundant.
In mouse experiments, researchers found that ImP reaching the brain increased the accumulation of abnormal beta-amyloid and tau proteins. Those proteins are associated with Alzheimer’s disease, but results in mice do not establish that the same mechanism causes disease in humans. In the human portion, the team examined blood samples from almost 1,200 participants in the Wisconsin Registry for Alzheimer’s Prevention and studies through the Wisconsin Alzheimer’s Disease Research Center.
Participants with higher blood ImP concentrations were more likely to have biological markers associated with abnormal proteins and impaired neuron function. Comparing those measurements with repeated cognitive tests, the researchers also found that people with higher ImP levels experienced faster cognitive decline. These are reported associations; the study material does not establish that ImP preceded or caused the changes in every participant.
A Possible Target Beyond Diet
The findings add a candidate link between gut bacteria and brain health to a field investigating how processes outside the brain may relate to dementia. If future studies establish that ImP contributes to disease rather than simply tracking with it, researchers could investigate whether reducing the molecule might affect risk or the pace of cognitive decline.
The authors do not recommend trying to eliminate histidine from food. It is an essential amino acid found in many foods, particularly protein-rich foods, and the study does not establish a dietary plan that lowers ImP or Alzheimer’s risk. University of Wisconsin–Madison professor Barbara Bendlin said a more targeted approach, such as a treatment that reduces ImP in the blood, might be worth investigating. No such treatment or preventive benefit was demonstrated in this research.
As an affiliate, we earn on qualifying purchases.
From Gut Microbes to ImP
Nearly a decade before this report, a team led by Barbara Bendlin and Federico Rey found that the intestinal microbial mix differed between people with Alzheimer’s and healthy individuals. Their subsequent work has sought to understand whether and how those differences relate to changes in the brain. The current study narrows attention to one bacterial product, ImP, rather than treating all gut microbes as having the same effects.
ImP has previously been linked in research to type 2 diabetes and coronary artery disease, according to the report. The new study extends investigation of the molecule to brain-related outcomes; it does not establish that those earlier associations or the new Alzheimer’s findings share one proven cause. Researchers from the University of California, Los Angeles, and the University of Gothenburg also contributed. Support included grants from the Wisconsin Partnership Program, the National Institutes of Health and the U.S. Department of Agriculture.
“Since then, we’ve been trying to figure out how this difference in the gut perhaps leads to changes in the brain.”
— Barbara Bendlin, University of Wisconsin–Madison professor of medicine
As an affiliate, we earn on qualifying purchases.
Cause and Treatment Remain Unknown
The human findings show a relationship between blood ImP levels, biological markers and cognitive change; they do not prove that ImP causes Alzheimer’s disease or that lowering it would change a person’s outcome. The report does not establish how much of the association might be explained by other health or biological factors, nor does it specify a clinically useful threshold for ImP in blood.
The researchers also identified a genetic variation associated with substantially higher ImP levels. About 43% of study participants carried it. The team suspects the variation may affect how efficiently the kidneys clear ImP from the blood, and Rey said the variation had previously been associated with Alzheimer’s risk in large genetic studies. The proposed kidney explanation remains a hypothesis in the report; the findings do not establish the precise mechanism. It is also unclear whether the results apply to populations beyond the Wisconsin participants.
As an affiliate, we earn on qualifying purchases.
Testing ImP-Lowering Strategies
The next step is to test whether ImP plays a causal role and whether changing its levels affects brain-related outcomes. The researchers say the molecule could offer a more specific target than attempting to remove histidine from the diet. Any proposed inhibitor would need to be developed and tested for safety and effectiveness; the study reports no approved ImP-lowering treatment or clinical recommendation.
Further research can also examine the genetic finding and the suspected role of kidney clearance, as well as whether ImP predicts changes in other groups of people. Until those questions are answered, the report supports continued investigation, not a change to Alzheimer’s prevention or treatment advice.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is imidazole propionate?
Imidazole propionate, or ImP, is a molecule produced by certain gut bacteria while they process histidine, an amino acid needed by the body.
Does this study prove ImP causes Alzheimer’s disease?
No. The mouse experiments linked ImP to abnormal amyloid and tau accumulation, while the human results showed associations with Alzheimer’s-related markers and faster cognitive decline. Those findings do not prove cause and effect in people.
Should people avoid histidine-rich foods?
The researchers did not recommend avoiding them. Histidine is essential and occurs in many foods, and the study did not test a diet intended to lower ImP or Alzheimer’s risk.
Is there a treatment that lowers ImP?
The study raises the possibility of developing an ImP-lowering treatment, but it does not report an available or proven drug, nor evidence that reducing ImP prevents Alzheimer’s disease.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
